Vanitha Ramakrishnan
Overview
Explore the profile of Vanitha Ramakrishnan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
839
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Treon S, Kotton C, Park D, Moranzoni G, Lemvigh C, Gathe Jr J, et al.
Front Immunol
. 2025 Feb;
15:1369619.
PMID: 39906744
Background: Cytokine release triggered by a hyperactive immune response is thought to contribute to severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2)-related respiratory failure. Bruton tyrosine kinase (BTK) is involved in...
2.
Xu L, Shadman M, Flinn I, Levy M, Porter R, Burke J, et al.
Haematologica
. 2024 Jan;
109(7):2284-2289.
PMID: 38268449
No abstract available.
3.
Tatarczuch M, Waltham M, Shortt J, Polekhina G, Hawkes E, Ho S, et al.
Blood Adv
. 2023 Mar;
7(14):3531-3539.
PMID: 36947202
Using tissue whole exome sequencing (WES) and circulating tumor cell-free DNA (ctDNA), this Australasian Leukaemia & Lymphoma Group translational study sought to characterize primary and acquired molecular determinants of response...
4.
Austin R, Lemon B, Aaron W, Barath M, Culp P, DuBridge R, et al.
Mol Cancer Ther
. 2020 Nov;
20(1):109-120.
PMID: 33203731
T cells have a unique capability to eliminate cancer cells and fight malignancies. Cancer cells have adopted multiple immune evasion mechanisms aimed at inhibiting T cells. Dramatically improved patient outcomes...
5.
Tam C, Robak T, Ghia P, Kahl B, Walker P, Janowski W, et al.
Haematologica
. 2020 Oct;
106(9):2354-2363.
PMID: 33054121
Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma whose tumors carry deletion of chromosome 17p13.1 [del(17p)] have an unfavorable prognosis and respond poorly to standard chemoimmunotherapy. Zanubrutinib is a...
6.
Stewart A, Krishnan A, Singhal S, Boccia R, Patel M, Niesvizky R, et al.
Blood Cancer J
. 2019 Feb;
9(2):17.
PMID: 30718503
FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E...
7.
Uppal H, Doudement E, Mahapatra K, Darbonne W, Bumbaca D, Shen B, et al.
Clin Cancer Res
. 2014 Nov;
21(1):123-33.
PMID: 25370470
Purpose: Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) comprising the cytotoxic agent DM1 conjugated to trastuzumab with a stable linker. Thrombocytopenia was the dose-limiting toxicity in the phase I study,...
8.
Koeppen H, Yu W, Zha J, Pandita A, Penuel E, Rangell L, et al.
Clin Cancer Res
. 2014 Apr;
20(17):4488-98.
PMID: 24687921
Purpose: In a recent phase II study of onartuzumab (MetMAb), patients whose non-small cell lung cancer (NSCLC) tissue scored as positive for MET protein by immunohistochemistry (IHC) experienced a significant...
9.
Patnaik A, LoRusso P, Messersmith W, Papadopoulos K, Gore L, Beeram M, et al.
Cancer Chemother Pharmacol
. 2014 Mar;
73(5):951-60.
PMID: 24633809
Purpose: MNRP1685A is a human monoclonal antibody that blocks binding of vascular endothelial growth factor (VEGF), VEGF-B, and placental growth factor 2 to neuropilin-1 resulting in vessel immaturity and VEGF...
10.
Yan Y, Serra V, Prudkin L, Scaltriti M, Murli S, Rodriguez O, et al.
Clin Cancer Res
. 2013 Oct;
19(24):6976-86.
PMID: 24141624
Purpose: The oncogenic PI3K/Akt/mTOR pathway is an attractive therapeutic target in cancer. However, it is unknown whether the pathway blockade required for tumor growth inhibition is clinically achievable. Therefore, we...